Pipeline Database
UB355
Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.
UB355
IndicationsTuberculosis
ClinicalCN - IND
TherapeuticsRespiratory
ModalitiesNucleic Acid Therapeutics
Exclusive Summary
- Pioneering Status: Positioned as one of the world's first TB mRNA vaccines to complete preclinical research and enter exploratory clinical trials (IIT), aiming for First-in-class status.
- Proprietary Platform: Developed on a fully independent mRNA platform with AI-assisted design and proprietary delivery systems, bypassing major IP barriers for global licensing.
- Addressing Global Unmet Needs: Targets Tuberculosis, a top global infectious killer where the century-old BCG vaccine lacks efficacy in adults; mRNA offers a promising solution for superior cellular immunity.
Asset Materials
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →